Analyst Insights: Walgreen, Barclays, Deutsche Bank, Las Vegas Sands March 26th

Walgreen Co. (NYSE:WAG): UBS expects Walgreen’s (NYSE:WAG) EPS comps to turn negative in Q2 given Express Scripts (NASDAQ:ESRX) dispute. The firm believes commentary regarding Express Scripts on the call will be more critical than earnings and they still expects a resolution in April/May. Shares of Walgreen are Buy rated with a $38 price target.

Barclays PLC (NYSE:BCS): Barclays named a long Research Tactical Idea at Morgan Stanley

Deutsche Bank AG (NYSE:DB): Deutsche Bank named a long Research Tactical Idea at Morgan Stanley

Las Vegas Sands Corp. (NYSE:LVS): Stifel Nicolaus expects Las Vegas Sands’ stock to outperform the market in coming months, boosted partly by the opening of its Cotai Central casino in Macau. The firm raised its target on the stock to $69 from $63 and maintains a Buy rating.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at